MedElevator Войти в исследования
← Поиск публикаций

DOI 10.21037/tlcr-2025-aw-1305

Медицинская библиотека · Translational lung cancer research · 2026

Adjuvant epidermal growth factor receptor tyrosine kinase inhibitor in resected stage N2 non-small cell lung cancer harboring EGFR mutation.

Xue Yinyin, Wu Qiang, Li Wen, Xu Feng, Li Yan, Zhou Qinghua

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Adjuvant therapy with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is effective and safe for patients with completely resected non-small cell lung cancer (NSCLC) with EGFR mutations, but certain issues remain unresolved. This retrospective study aimed to investigate the optimal adjuvant treatment regimen and duration of EGFR-TKI treatment, evaluate the efficacy of different generations of EGFR-TKIs, and identify prognostic factors for patients with stage N2 EGFR-mutant NSCLC.

METHODS

From July 31, 2010, to July 31, 2022, clinicopathological data were collected from 190 patients with N2 EGFR-mutant NSCLC who underwent complete surgical resections. Patients received either postoperative adjuvant EGFR-TKI monotherapy or adjuvant combination therapy with EGFR-TKI (chemotherapy, radiotherapy, or radiochemotherapy prior to EGFR-TKI therapy). Overall survival (OS) and disease-free survival (DFS) were assessed.

RESULTS

The median follow-up of the 190 patients was 49 months, with a 4-year DFS rate being 41.3% and the 4-year OS rate being 80.2%. Among these patients, 127 (66.8%) received EGFR-TKI monotherapy, while 63 (33.2%) received combination therapy. Pathological tumor-node-metastasis (pTNM) stage (stage IIIA vs. stage IIIB; P=0.01) and generation of EGFR-TKI (third vs. first; P<0.001) were significantly associated with DFS benefit, but not with OS. The number of positive mediastinal lymph nodes (<3 vs. ≥3) correlated with both DFS (P=0.02) and OS (P=0.04) benefit. EGFR mutation status (exon 19 deletion vs. exon 21 L858R point mutation) was significantly associated with DFS (P=0.03) and OS (P=0.01). However, EGFR-TKI monotherapy and combination therapy demonstrated no significant differences in terms of DFS (P=0.73) or OS (P=0.13). Longer duration of EGFR-TKI treatment (>3 vs. ≤3 years) was associated with better DFS (P<0.001) and OS (P<0.001). Moreover, pTNM stage, generation of EGFR-TKI, and duration of EGFR-TKI treatment were identified as independent prognostic factors for DFS (all P<0.05), while duration of EGFR-TKI treatment was also an independent prognostic factor for OS (P<0.001).

CONCLUSIONS

Our study found that EGFR-TKI monotherapy and combination therapy demonstrated no significant differences in terms of DFS or OS in patients with completely resected stage N2 EGFR-mutant NSCLC. Adjuvant treatment with third-generation EGFR-TKIs and prolonged treatment duration may offer enhanced survival benefits.

Для цитирования: Xue Yinyin, Wu Qiang, Li Wen, Xu Feng, Li Yan, Zhou Qinghua. Adjuvant epidermal growth factor receptor tyrosine kinase inhibitor in resected stage N2 non-small cell lung cancer harboring EGFR mutation.. Translational lung cancer research. 2026. DOI: 10.21037/tlcr-2025-aw-1305.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.